Cargando…
The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP wou...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447648/ https://www.ncbi.nlm.nih.gov/pubmed/30984619 http://dx.doi.org/10.3389/fonc.2019.00193 |
_version_ | 1783408539012694016 |
---|---|
author | Cuyàs, Elisabet Buxó, Maria Ferri Iglesias, Maria José Verdura, Sara Pernas, Sonia Dorca, Joan Álvarez, Isabel Martínez, Susana Pérez-Garcia, Jose Manuel Batista-López, Norberto Rodríguez-Sánchez, César A. Amillano, Kepa Domínguez, Severina Luque, Maria Morilla, Idoia Stradella, Agostina Viñas, Gemma Cortés, Javier Joven, Jorge Brunet, Joan López-Bonet, Eugeni Garcia, Margarita Saidani, Samiha Queralt Moles, Xavier Martin-Castillo, Begoña Menendez, Javier A. |
author_facet | Cuyàs, Elisabet Buxó, Maria Ferri Iglesias, Maria José Verdura, Sara Pernas, Sonia Dorca, Joan Álvarez, Isabel Martínez, Susana Pérez-Garcia, Jose Manuel Batista-López, Norberto Rodríguez-Sánchez, César A. Amillano, Kepa Domínguez, Severina Luque, Maria Morilla, Idoia Stradella, Agostina Viñas, Gemma Cortés, Javier Joven, Jorge Brunet, Joan López-Bonet, Eugeni Garcia, Margarita Saidani, Samiha Queralt Moles, Xavier Martin-Castillo, Begoña Menendez, Javier A. |
author_sort | Cuyàs, Elisabet |
collection | PubMed |
description | Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP would predict clinical response to neoadjuvant metformin in women with early breast cancer (BC). Methods: DNA was collected from 79 patients included in the intention-to-treat population of the METTEN study, a phase 2 clinical trial of HER2-positive BC patients randomized to receive either metformin combined with anthracycline/taxane-based chemotherapy and trastuzumab or equivalent regimen without metformin, before surgery. SNP rs11212617 genotyping was assessed using allelic discrimination by quantitative polymerase chain reaction. Results: Logistic regression analyses revealed a significant relationship between the rs11212617 genotype and the ability of treatment arms to achieve a pathological complete response (pCR) in patients (odds ratio [OR](genotype×arm) = 10.33, 95% confidence interval [CI]: 1.29–82.89, p = 0.028). In the metformin-containing arm, patients bearing the rs11212617 C allele had a significantly higher probability of pCR (OR(A/C,C/C) = 7.94, 95%CI: 1.60–39.42, p = 0.011). Conversely, no association was found between rs11212617 and clinical response in the reference arm (OR(A/C,C/C) = 0.77, 95%CI: 0.20–2.92, p = 0.700). After controlling for tumor size and hormone receptor status, the rs11212617 C allele remained a significant predictor of pCR solely in the metformin-containing arm. Conclusions: If reproducible, the rs11212617 C allele might warrant consideration as a predictive clinical biomarker to inform the personalized use of metformin in BC patients. Trial Registration: EU Clinical Trials Register, EudraCT number 2011-000490-30. Registered 28 February 2011, https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000490-30/ES. |
format | Online Article Text |
id | pubmed-6447648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64476482019-04-12 The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin Cuyàs, Elisabet Buxó, Maria Ferri Iglesias, Maria José Verdura, Sara Pernas, Sonia Dorca, Joan Álvarez, Isabel Martínez, Susana Pérez-Garcia, Jose Manuel Batista-López, Norberto Rodríguez-Sánchez, César A. Amillano, Kepa Domínguez, Severina Luque, Maria Morilla, Idoia Stradella, Agostina Viñas, Gemma Cortés, Javier Joven, Jorge Brunet, Joan López-Bonet, Eugeni Garcia, Margarita Saidani, Samiha Queralt Moles, Xavier Martin-Castillo, Begoña Menendez, Javier A. Front Oncol Oncology Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP would predict clinical response to neoadjuvant metformin in women with early breast cancer (BC). Methods: DNA was collected from 79 patients included in the intention-to-treat population of the METTEN study, a phase 2 clinical trial of HER2-positive BC patients randomized to receive either metformin combined with anthracycline/taxane-based chemotherapy and trastuzumab or equivalent regimen without metformin, before surgery. SNP rs11212617 genotyping was assessed using allelic discrimination by quantitative polymerase chain reaction. Results: Logistic regression analyses revealed a significant relationship between the rs11212617 genotype and the ability of treatment arms to achieve a pathological complete response (pCR) in patients (odds ratio [OR](genotype×arm) = 10.33, 95% confidence interval [CI]: 1.29–82.89, p = 0.028). In the metformin-containing arm, patients bearing the rs11212617 C allele had a significantly higher probability of pCR (OR(A/C,C/C) = 7.94, 95%CI: 1.60–39.42, p = 0.011). Conversely, no association was found between rs11212617 and clinical response in the reference arm (OR(A/C,C/C) = 0.77, 95%CI: 0.20–2.92, p = 0.700). After controlling for tumor size and hormone receptor status, the rs11212617 C allele remained a significant predictor of pCR solely in the metformin-containing arm. Conclusions: If reproducible, the rs11212617 C allele might warrant consideration as a predictive clinical biomarker to inform the personalized use of metformin in BC patients. Trial Registration: EU Clinical Trials Register, EudraCT number 2011-000490-30. Registered 28 February 2011, https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000490-30/ES. Frontiers Media S.A. 2019-03-28 /pmc/articles/PMC6447648/ /pubmed/30984619 http://dx.doi.org/10.3389/fonc.2019.00193 Text en Copyright © 2019 Cuyàs, Buxó, Ferri Iglesias, Verdura, Pernas, Dorca, Álvarez, Martínez, Pérez-Garcia, Batista-López, Rodríguez-Sánchez, Amillano, Domínguez, Luque, Morilla, Stradella, Viñas, Cortés, Joven, Brunet, López-Bonet, Garcia, Saidani, Queralt Moles, Martin-Castillo and Menendez. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Cuyàs, Elisabet Buxó, Maria Ferri Iglesias, Maria José Verdura, Sara Pernas, Sonia Dorca, Joan Álvarez, Isabel Martínez, Susana Pérez-Garcia, Jose Manuel Batista-López, Norberto Rodríguez-Sánchez, César A. Amillano, Kepa Domínguez, Severina Luque, Maria Morilla, Idoia Stradella, Agostina Viñas, Gemma Cortés, Javier Joven, Jorge Brunet, Joan López-Bonet, Eugeni Garcia, Margarita Saidani, Samiha Queralt Moles, Xavier Martin-Castillo, Begoña Menendez, Javier A. The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin |
title | The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin |
title_full | The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin |
title_fullStr | The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin |
title_full_unstemmed | The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin |
title_short | The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin |
title_sort | c allele of atm rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447648/ https://www.ncbi.nlm.nih.gov/pubmed/30984619 http://dx.doi.org/10.3389/fonc.2019.00193 |
work_keys_str_mv | AT cuyaselisabet thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT buxomaria thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT ferriiglesiasmariajose thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT verdurasara thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT pernassonia thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT dorcajoan thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT alvarezisabel thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT martinezsusana thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT perezgarciajosemanuel thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT batistalopeznorberto thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT rodriguezsanchezcesara thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT amillanokepa thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT dominguezseverina thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT luquemaria thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT morillaidoia thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT stradellaagostina thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT vinasgemma thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT cortesjavier thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT jovenjorge thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT brunetjoan thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT lopezboneteugeni thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT garciamargarita thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT saidanisamiha thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT queraltmolesxavier thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT martincastillobegona thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT menendezjaviera thecalleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT cuyaselisabet calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT buxomaria calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT ferriiglesiasmariajose calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT verdurasara calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT pernassonia calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT dorcajoan calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT alvarezisabel calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT martinezsusana calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT perezgarciajosemanuel calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT batistalopeznorberto calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT rodriguezsanchezcesara calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT amillanokepa calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT dominguezseverina calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT luquemaria calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT morillaidoia calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT stradellaagostina calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT vinasgemma calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT cortesjavier calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT jovenjorge calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT brunetjoan calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT lopezboneteugeni calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT garciamargarita calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT saidanisamiha calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT queraltmolesxavier calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT martincastillobegona calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin AT menendezjaviera calleleofatmrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin |